Enlivex Therapeutics (ENLV) Competitors $1.08 +0.02 (+1.41%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.08 +0.00 (+0.46%) As of 06:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. ANRO, ANEB, CNTB, CRVO, IPA, ANIX, ALTS, VIRI, ENTX, and ORMPShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Alto Neuroscience (ANRO), Anebulo Pharmaceuticals (ANEB), Connect Biopharma (CNTB), CervoMed (CRVO), ImmunoPrecise Antibodies (IPA), Anixa Biosciences (ANIX), ALT5 Sigma (ALTS), Virios Therapeutics (VIRI), Entera Bio (ENTX), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Its Competitors Alto Neuroscience Anebulo Pharmaceuticals Connect Biopharma CervoMed ImmunoPrecise Antibodies Anixa Biosciences ALT5 Sigma Virios Therapeutics Entera Bio Oramed Pharmaceuticals Alto Neuroscience (NYSE:ANRO) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings. Does the media refer more to ANRO or ENLV? In the previous week, Alto Neuroscience had 17 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 25 mentions for Alto Neuroscience and 8 mentions for Enlivex Therapeutics. Alto Neuroscience's average media sentiment score of 0.18 beat Enlivex Therapeutics' score of 0.15 indicating that Alto Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ANRO or ENLV? Alto Neuroscience presently has a consensus price target of $8.50, indicating a potential upside of 115.74%. Enlivex Therapeutics has a consensus price target of $10.00, indicating a potential upside of 825.93%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ANRO or ENLV more profitable? Alto Neuroscience's return on equity of -44.34% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -44.34% -36.73% Enlivex Therapeutics N/A -58.31%-50.32% Do insiders & institutionals have more ownership in ANRO or ENLV? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable valuation & earnings, ANRO or ENLV? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$61.43M-$2.39-1.65Enlivex TherapeuticsN/AN/A-$15.01M-$0.58-1.86 Which has more volatility & risk, ANRO or ENLV? Alto Neuroscience has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. SummaryAlto Neuroscience beats Enlivex Therapeutics on 7 of the 13 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.19M$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio-1.8623.4976.3826.51Price / SalesN/A672.77521.37123.58Price / CashN/A169.4937.1760.46Price / Book1.085.3313.666.29Net Income-$15.01M$32.95M$3.28B$270.51M7 Day Performance6.40%0.10%0.88%1.95%1 Month Performance-40.66%3.91%4.67%6.33%1 Year Performance-28.48%-3.91%80.92%25.62% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics2.5372 of 5 stars$1.08+1.4%$10.00+825.9%-29.9%$25.19MN/A-1.8670ANROAlto Neuroscience2.74 of 5 stars$3.91+6.5%$8.50+117.4%-71.7%$99.37MN/A-1.64N/AANEBAnebulo Pharmaceuticals2.1107 of 5 stars$2.20-7.6%$5.50+150.0%+19.1%$97.78MN/A-8.464News CoverageUpcoming EarningsHigh Trading VolumeCNTBConnect Biopharma3.6958 of 5 stars$1.79+2.3%$7.00+291.1%+36.4%$97.51M$26.03M0.00110News CoverageAnalyst RevisionGap UpCRVOCervoMed3.8201 of 5 stars$9.99-4.9%$19.29+93.1%-49.9%$97.25M$9.74M-3.834Positive NewsIPAImmunoPrecise Antibodies2.6182 of 5 stars$2.10+8.5%$4.00+90.9%+284.4%$96.68M$17.59M-3.0880Gap UpANIXAnixa Biosciences3.1194 of 5 stars$2.98+0.3%$9.00+202.0%+9.1%$95.67M$210K-7.845Earnings ReportAnalyst RevisionALTSALT5 Sigma0.1817 of 5 stars$4.13-5.9%N/A+84.5%$94.97M$12.53M0.00170Gap UpVIRIVirios TherapeuticsN/A$4.90-2.0%$5.00+2.0%+2,379.8%$94.36MN/A-18.155ENTXEntera Bio1.4839 of 5 stars$2.00-2.9%$10.00+400.0%-9.5%$94.07M$180K-7.6920Positive NewsHigh Trading VolumeORMPOramed Pharmaceuticals0.8523 of 5 stars$2.30+3.1%N/A-7.7%$91.44M$1.34M-6.5710 Related Companies and Tools Related Companies ANRO Competitors ANEB Competitors CNTB Competitors CRVO Competitors IPA Competitors ANIX Competitors ALTS Competitors VIRI Competitors ENTX Competitors ORMP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
